EN DE
Watch Afya Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Afya Ltd (AFYA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Afya Ltd stock $30.27, price $10.09, upside +200.0%, quality 69 out of 100. Rating: strongly undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive US · Based in Brazil · ISIN KYG011251066

AL Afya Ltd logo Thin data Nov 16, 2026

Afya Ltd

AFYA · US

Cheap (67% below fair value), solid company and rising price: meets all 3 rules.

Get notified free when this changes
Fair value $30.27 · Strongly undervalued 
Quality 69/100 
Rising price (uptrend) 
Healthy Growth (revenue 5y +24.7 %/yr in BRL) 
Highly profitable · 20.4% net margin (TTM) 
Low debt 
Generates free cash flow 
6.5% dividend yield · Well covered
Ranks above peers (12/13) 
Even on cautious assumptions the value is 81% above the price ($18.27). 
Wide moat 74/100 · thin data
Insiders sold $1.4M (6M) 
Thin data 
⚠ Small free float
Watch Afya Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$21.27 $8.53 Fair Value $30.27 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $8.53 – $21.27 · fair‑value band $18.27 – $39.36 · the $10.09 price screens below the $30.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Afya in your weekly email

Every Wednesday you see whether Afya is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Afya Limited operates as a medical education group in Brazil. The company operates in three segments: Undergraduate, Continuing Education, and Medical Practice Solutions.

Show moreShow less

The Undergraduate segment offers educational services through undergraduate courses related to medical school, health sciences, and other non-health undergraduate programs, including medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, biomedicine, business administration, accounting, law, civil and industrial engineering, and pedagogy.

The Continuing Education segment provides medical education, including residency preparation programs, specialization test preparation, graduate courses in medicine, and digital and in-person professional development for physicians and medical students.

The Medical Practice Solutions segment offers clinical decision support platforms, medical practice management software, healthcare financial services, and digital healthcare ecosystem solutions, such as electronic medical records, practice management tools, telemedicine, digital prescriptions, and doctor-patient relationship platforms.

This segment also provides a subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others.

The company also offers educational health and medical imaging; and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

In addition, it offers printed and digital content, as well as an online medical education platform and physicians, healthcare professionals and students. Afya Limited was founded in 1999 and is headquartered in Belo Horizonte, Brazil.

Stock analysis

Afya Ltd (AFYA) currently trades at $10.09, while our model-based Fair Value estimate is $30.27, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $63.20 per share, and 20 of the 22 models we run sit above the $10.09 price.

Bear case: the Economic Profit group reads lowest at $22.85, and 2 of the 22 models stay below the price. Data coverage for this calculation is low.

Scenario range: $18.27 (bear) to $39.36 (bull), the price of $10.09 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Consumer Defensive sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Afya Ltd reported revenue of R$3.6B in FY2025 versus R$1.7B in FY2021, a compound +20.5%/yr. Reported net income was R$738M in FY2025, compounding +34.8%/yr from FY2021.

Key figures

Market cap $901M Small · P/E ratio 6.3 · P/S ratio 1.28 · EPS (TTM) $1.64 · Dividend yield 6.5% · Net margin 20.4% · Return on equity 16.7% · Return on assets (EBIT) 10.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 74 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 36% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 30% fair-value upside, at 200%, AFYA screens cheaper than that median.

Fair Value models

Bear $18.27 Fair Value $30.27 Bull $39.36
Price $10.09 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then ($0.8643 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $42.73 $65.82 $137.00 75
Growth DCF $39.99 $71.77 $132.90 74
Residual Income $9.29 $11.96 $18.13 73
All 22 models by family
DCF Models
FCF DCF $42.73 $65.82 $137.00 75
Owner Earnings $31.48 $70.66 $148.20 70
5Y Revenue Exit $15.99 $23.03 $37.29 71
5Y EBITDA Exit $31.35 $54.08 $98.55 71
5Y P/E Exit $28.66 $60.57 $103.10 67
10Y Revenue Exit $24.24 $41.66 $48.57 67
10Y EBITDA Exit $35.29 $73.50 $137.87 64
10Y P/E Exit $33.40 $67.92 $122.46 60
Earnings-Based
Graham-Dodd $9.80 $68.37 $95.95 60
Lynch FV $28.74 $41.06 $53.38 58
PEG = 1.0 $28.74 $41.06 $53.38 55
EPV $16.77 $19.59 $22.01 72
Multiples
P/E Multiple $23.79 $31.72 $39.65 61
P/S Multiple $6.38 $8.50 $10.63 56
EV/EBIT $27.49 $37.95 $48.41 64
EV/EBITDA $23.59 $32.76 $41.92 66
EV/Revenue $2.05 $4.60 $7.16 50
Growth DCF
Growth DCF $39.99 $71.77 $132.90 74
Rev-Margin DCF $16.59 $26.68 $46.41 69
Economic Profit
Residual Income $9.29 $11.96 $18.13 73
ROIC Compounder $22.40 $33.73 $40.69 71
Growth Earnings
Growth-Adj P/E $36.36 $51.94 $67.53 66

Open the full fair value analysis →

Quality Score breakdown

Overall quality 69/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 53
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 90
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 55
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 94
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $1.4M and none bought.

  • SaleSantos Welder FerreiraController2× since Apr 17, 2026: 7,486 shares, avg. $14.45$108,209Oct 5, 2026
  • SaleLelio de Souza JuniorVice President4× since Apr 7, 2026: 120,777 shares, avg. $14.93$1.8MJul 1, 2026
  • SaleGomiero Mirella BasolliVice President10,000 shares at $14.80$148,000Jun 26, 2026
  • SaleDe Sousa Anibal Jose GrifoVP Legal, Comp., & Gov Rel.2× since Apr 7, 2026: 19,000 shares, avg. $15.36$291,770Apr 13, 2026
  • SaleLuis Andre Carpintero BlancoChief Financial Officer10,000 shares at $15.20$152,000Apr 8, 2026
  • SaleVirgilio Deloy Capobianco GibbonChief Executive Officer4× since Mar 25, 2026: 50,000 shares, avg. $14.98$748,835Apr 6, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.3%
What shareholders gained per year (last 5 years), in BRL (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in BRL: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+31.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+24.8%
Dividend (yield on the price)6.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 33%
2025 sits 89% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Watch AFYA, get fair value alerts →

Compare Afya Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Education & Training Services · 114 stocks

Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 69 · Above median
Fair Value upside +200.0% · Top 25%
Profitability
Return on equity (12 months) 16.7% · Top 25%
Return on assets 7.9% · Top 25%
Net margin (12 months) 20.4% · Top 25%
Operating margin (12 months) 32.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 5.7% · Above median
Dividend yield (12 months) 6.5% · Top 25%
Balance sheet
Debt / equity 0.41× · Above median

Valuation Multiplesvs Education & Training Services median · lower = cheaper

P/E (12 months) 6.3× · Cheapest 25%
P/B 1.06× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 1.35× · Cheaper than median
Price / free cash flow (fiscal year) 5.0× · Cheapest 25%
EV/EBITDA 4.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 32
FUTURE (revenue growth)29 · sector 11
PAST (return on equity)67 · sector 19
HEALTH (low debt)79 · sector 95
DIVIDEND (yield)100 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Education & Training Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stride, Inc LRN $76.55 $171.72 +124% vs AFYA
New Oriental Education & Technology Group 9901 HK$41.88 HK$64.56 +54% vs AFYA
Perdoceo Education Corporation PRDO $28.95 $41.20 +42% vs AFYA
Covista Inc CVSA $117.74 $152.79 +30% vs AFYA
Grand Canyon Education, Inc LOPE $119.31 $154.63 +30% vs AFYA
Laureate Education, Inc LAUR $34.54 $42.74 +24% vs AFYA
East Buy Holding 1797 HK$29.60 HK$31.39 +6% vs AFYA
Youdao, Inc DAO $19.55 $18.57 −5% vs AFYA
McGraw Hill, Inc MH $11.89 $8.95 −25% vs AFYA
Physicswallah Limited PWL ₹129.45 ₹31.71 −76% vs AFYA

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Afya Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Afya Ltd Fair Value". https://www.fairvalue-calculator.com/stock/AFYA

Frequently asked questions

Is Afya Ltd (AFYA) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of $30.27 versus a price of $10.09, about +200% upside (undervalued).
What is the fair value of AFYA?
Our model-based fair value for Afya Ltd is $30.27 (as of Nov 16, 2026), built from audited fundamentals. The current price: $10.09.
What is the quality score of AFYA?
Afya Ltd has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Afya Ltd (AFYA)?
Our model-based price target is the fair value of $30.27 (as of Nov 16, 2026) from 22 valuation models. Cautious scenario $18.27, optimistic scenario $39.36. It is a calculation from audited fundamentals, not an analyst target.
What is the Afya Ltd stock forecast for 2026?
Our models put fair value at $30.27, about +200% upside versus a price of $10.09 (undervalued). Cautious scenario $18.27, optimistic scenario $39.36. The calculation is refreshed regularly with new filings.
What is the revenue of Afya Ltd (AFYA)?
Afya Ltd reported trailing-twelve-month revenue of about R$3.8B (latest available figure, as of Nov 16, 2026).
Does Afya Ltd pay a dividend?
Afya Ltd currently shows a dividend yield of 6.51% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Afya Ltd (AFYA) and when is the ex-dividend date?
Afya Ltd pays a dividend of $0.657 per share a year, a dividend yield of 6.5%. The last ex-dividend date was Mar 25, 2026. The payout ratio is 25.4% of earnings. Free cash flow covers the dividend 5.52 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What is the intrinsic value of Afya Ltd (AFYA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Afya Ltd it is $30.27 per share (as of Nov 16, 2026), against a price of $10.09. It is the blended result of 22 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Afya Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, AFYA trades below its calculated fair value: price $10.09, fair value $30.27, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AFYA?
No. The price is what the market pays today ($10.09); the fair value is what the company's own numbers justify ($30.27). For Afya Ltd the two are $20.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Afya Ltd worth?
The market values Afya Ltd at about $901M (market capitalisation, as of Nov 16, 2026). Per share that is $10.09; our models calculate a fair value of $30.27 per share.
What do the bullish and bearish scenarios say about AFYA?
Our models span a range for Afya Ltd: cautious scenario $18.27, base $30.27, optimistic $39.36 per share (as of Nov 16, 2026, price $10.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AFYA?
Afya Ltd trades at a price-to-earnings ratio of 6.3 (as of Nov 16, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $30.27 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 24.9. Other multiples: P/B 1.1, P/S 1.3, EV/EBITDA 4.1.
How solid is the balance sheet of Afya Ltd (AFYA)?
Balance-sheet figures for Afya Ltd (as of Nov 16, 2026): return on equity 16.7%, debt of 0.41 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is AFYA from its 52-week high?
Afya Ltd trades at $10.09, about 36% below its 52-week high of $15.86 and at the low of $10.09 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $30.27 is for.
Which stocks are comparable to Afya Ltd?
From the same area (Consumer Defensive) we also value New Oriental Education & Technology Group, Laureate Education, Inc, Covista Inc, Physicswallah Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Afya Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price $10.09, calculated fair value $30.27 (+200%), Quality Score 69/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AFYA calculated?
We run Afya Ltd through 22 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $30.27 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Afya Ltd currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Afya Ltd (AFYA)?
The closing price on Nov 16, 2026 was $10.09. Our model-based fair value is $30.27, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Afya Ltd right now?
The price is below even our cautious bear case ($18.27). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($18.27 to $39.36) leaves room in how you read the outcome.

Key figures of Afya Ltd

How large is the market capitalisation of Afya Ltd (AFYA)?
The market capitalisation of Afya Ltd is $901M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Afya Ltd (AFYA)?
The price-to-sales ratio of Afya Ltd is 1.28 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Afya Ltd (AFYA)?
Earnings per share at Afya Ltd are $1.64 (price ÷ EPS = P/E 6.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Afya Ltd (AFYA)?
The dividend yield of Afya Ltd is 6.5% (payout 40.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Afya Ltd (AFYA)?
The net margin of Afya Ltd is 20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Afya Ltd (AFYA)?
The return on equity (ROE) of Afya Ltd is 16.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Afya Ltd (AFYA)?
On an EBIT basis the return on assets of Afya Ltd is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Afya Ltd (AFYA)?
The operating margin of Afya Ltd is 32.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Afya Ltd (AFYA)?
Revenue at Afya Ltd is growing 5.7% versus a year earlier (3y avg +15.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Afya Ltd (AFYA)?
Earnings per share at Afya Ltd are growing 17.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Afya Ltd (AFYA) generate?
The free cash flow of Afya Ltd is $1.0B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Afya Ltd (AFYA) carry?
The net debt of Afya Ltd is $2.0B (fiscal year 2025, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Afya Ltd in the live analysis

One click puts Afya Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.